Education
About Us
Working with TipRanks
Follow Us
UCB SA (UCBJY)
OTHER OTC:UCBJY
UCBJY Stock Chart & Stats
$165.60
$1.86(1.89%)
At close: 4:00 PM EST
$165.60
$1.86(1.89%)
Day’s Range― - ―
52-Week Range$71.39 - $165.60
Previous CloseN/A
Volume2.14K
Average Volume (3M)2.85K
Market Cap
$62.89B
Enterprise Value$54.37B
Total Cash (Recent Filing)$2.01B
Total Debt (Recent Filing)$2.88B
Price to Earnings (P/E)43.5
Beta0.53
Next Earnings
Feb 26, 2026EPS Estimate
3.16Next Dividend Ex-DateN/A
Dividend Yield0.55%
Share Statistics
EPS (TTM)2.02
Shares Outstanding389,011,320
10 Day Avg. Volume1,843
30 Day Avg. Volume2,850
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)3.62
Price to Sales (P/S)5.90
P/FCF Ratio39.43
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue7.94
Enterprise Value/Gross Profit10.82
Enterprise Value/Ebitda23.38
Forecast
1Y Price Target
$165.00Price Target Upside-0.36% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Label Expansions And PipelinePlanned label expansions and ongoing clinical development, including a pediatric Phase III study in hidradenitis suppurativa, could broaden Bimzelx's addressable market and future revenue opportunities.
Management StrategyManagement's focused approach to support clinician uptake, preserve patient access, and target patients switching from other biologic therapies reinforces confidence in sustained market leadership for Bimzelx.
Product AdoptionRapid adoption of Bimzelx by specialist physicians for hidradenitis suppurativa and other skin and joint conditions is driving stronger-than-expected sales momentum.
Bears Say
Adoption SensitivityElevated sales expectations make the stock sensitive to any slower-than-anticipated patient uptake or lower clinician adoption rates in the emerging hidradenitis suppurativa segment.
Market Growth RiskInvestor skepticism about a possible slowdown in the hidradenitis suppurativa market may create uncertainty around future sales forecasts.
Valuation HeadwindsMacroeconomic pressures and perceived competitive overhang have contributed to a valuation discount that could constrain share appreciation absent stronger clinical or commercial evidence.
UCB SA News
UCBJY FAQ
What was UCB SA’s price range in the past 12 months?
UCB SA lowest stock price was $71.39 and its highest was $165.60 in the past 12 months.
What is UCB SA’s market cap?
UCB SA’s market cap is $62.89B.
When is UCB SA’s upcoming earnings report date?
UCB SA’s upcoming earnings report date is Feb 26, 2026 which is in 9 days.
How were UCB SA’s earnings last quarter?
UCB SA released its earnings results on Jul 31, 2025. The company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.927 by $0.093.
Is UCB SA overvalued?
According to Wall Street analysts UCB SA’s price is currently Overvalued.
Does UCB SA pay dividends?
UCB SA pays a Annually dividend of $0.79 which represents an annual dividend yield of 0.55%. See more information on UCB SA dividends here
What is UCB SA’s EPS estimate?
UCB SA’s EPS estimate is 3.16.
How many shares outstanding does UCB SA have?
UCB SA has 389,011,320 shares outstanding.
What happened to UCB SA’s price movement after its last earnings report?
UCB SA reported an EPS of $2.02 in its last earnings report, beating expectations of $1.927. Following the earnings report the stock price went up 2.414%.
Which hedge fund is a major shareholder of UCB SA?
Currently, no hedge funds are holding shares in UCBJY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
UCB SA Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$165.00 (-0.36% Downside)
$165.00 (-0.36% Downside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.69%
12-Months-Change
Fundamentals
Return on Equity
13.80%
Trailing 12-Months
Asset Growth
20.44%
Trailing 12-Months
Company Description
UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
UCBJY Stock 12 Month Forecast
Average Price Target
$165.00
▼(-0.36% Downside)
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---